Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 9, 2007, to announce its financial results for the first quarter ended March 31, 2007. This filing primarily serves to furnish the press release detailing these results, rather than disclosing new material events. Investors should refer to the press release (Exhibit 99.1) for specific financial performance and operational updates from that period. The report indicates that the information provided is for informational purposes and is furnished, not filed, under SEC rules. This means it will not be subject to the liabilities of Section 18 of the Exchange Act unless expressly incorporated by reference into another filing. Therefore, for a deep dive into the financial condition and results of operations for Q1 2007, investors need to access the full press release mentioned in the filing.
Key Highlights
- 1Alnylam Pharmaceuticals, Inc. reported its financial results for the quarter ended March 31, 2007, on May 9, 2007.
- 2The primary purpose of the 8-K filing was to furnish a press release detailing these financial results.
- 3The press release, dated May 9, 2007, is included as Exhibit 99.1 to the 8-K.
- 4The filing clarifies that the information furnished is not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.
- 5This 8-K does not contain new material events beyond the earnings announcement.
- 6Investors are directed to Exhibit 99.1 for specific details on the company's financial performance and operational status for the first quarter of 2007.